Schrödinger (SDGR) Stock May Be Below Fair Value On Tectora Deal

Schrödinger has had a powerful run in 2026, which puts a fresh spotlight on a simple question for anyone looking at the stock today. Is the current share price adequately supported by the cash flows that the business can generate over time, based on a Discounted Cash Flow (DCF) view of intrinsic value?

• The stock is up 70.7% year to date. This means a lot of optimism is now embedded in the share price and puts more weight on what the company’s future cash flows can justify.
• Recent RSU grants and the creation of Tectora may support expectations for future drug discovery programs and potential royalty streams, which can affect both the timing and durability of Schrödinger’s cash generation.
• What if you looked at Schrödinger through its sales instead? See why Schrödinger's 8.9x P/S tells a different valuation story.

For investors, the debate is whether Schrödinger’s current valuation is properly aligned with the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.

If you want to pressure test Schrödinger’s cash flow story against other opportunities, it can help to scan a wider field using 29 high quality undervalued stocks.

Does Schrödinger Look Undervalued on Cash Flow?

The Discounted Cash Flow model values Schrödinger on the cash it might generate for shareholders over time rather than today’s accounting earnings. Latest twelve month free cash flow sits at a loss of $133.9 million. The projections used in this model assume that free cash flow shifts into positive territory and then grows over the coming decade, moving from expected annual losses in the near term to rising surpluses by 2030 and beyond.

This pattern points to a business still in investment mode, where the heavy spending needed for its platform and pipeline is expected to ease as collaborations and potential royalties scale. Because the Discounted Cash Flow projections put Schrödinger's estimated intrinsic value meaningfully above the current share price of $30.70, the market price implies a fair bit of doubt around how much of that future cash conversion will materialise. The recent Tectora collaboration, which brings potential milestones and royalty streams tied to immunology and inflammation programs, helps explain why some investors are prepared to underwrite those longer dated cash flows. Find out what Schrödinger could be worth using our Discounted Cash Flow (DCF) estimate.

The Schrödinger Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Schrödinger pick up where this valuation puzzle leaves off and explain what path for Schrödinger's growth, profitability and earnings would need to occur for the stock to be worth materially more or less than today's price on the cash flow numbers. Each narrative is set up as a specific, trackable claim about the business rather than a one off fair value snapshot, and it sits on the Simply Wall St Community page so you can revisit the same thesis over time.

Community views on Schrödinger split between a high-conviction cash flow upside story and a more cautious take that focuses on execution risk and concentration.

Bull case: 29% undervalued

"The bull case for Schrödinger is built on this durable business architecture and the platform's extensive validation, demonstrated by its contribution to FDA-approved drugs (TIBSOVO®, IDHIFA®) and its role in several high-value industry transactions (e.g., Nimbus/Takeda, Morphic/Lilly)..."

Discover why this Narrative puts Schrödinger at 29% undervalued.

Bear case: 81% overvalued

"Heavy reliance on existing large customers, margin pressures, sector challenges, dependence on milestone payments, and cost-cutting measures all threaten stable future growth and profitability..."

Explore why this Narrative puts Schrödinger at 81% overvalued.

One more Schrödinger factor investors should not skip

Schrödinger’s story is not only about potential cash flows and partnerships, since the research checks on this business also flag specific caution signs that deserve a closer look from anyone considering the stock. Take a closer look at 3 warning signs (1 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com